The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study to evaluate the ability of decitabine and panobinostat to improve temozolomide chemosensitivity in metastatic melanoma.
Chang Xia
No relevant relationships to disclose
Douglas Earl Laux
No relevant relationships to disclose
Jeremy Michael Deutsch
No relevant relationships to disclose
Melanie Frees
No relevant relationships to disclose
Brian Smith
No relevant relationships to disclose
Raymond J. Hohl
No relevant relationships to disclose
Mohammed M. Milhem
Research Funding - Novartis